So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
XtalPi scores landmark deal for AI drug discovery
The biotech has partnered with U.S. firm DoveTree in a collaboration worth up to $5.99 billion, adding to a slew of major deals for Chinese research firms this year Key…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
FAST NEWS: 3SBio Sees Profit Doubling on Surging Revenues
The latest: 3SBio Inc. (1530.HK) released a positive profit forecast on Monday evening, estimating its net profit rose 100% to 120% for 2021, while its profit attributable to equity shareholders…
Recent Articles
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
InnoCare licensing deal flops due to lack of upfront cash
9969.HK 688428.SHG
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
